Glenmark receives tentative US FDA approval for psoriasis drug
The company has been granted tentative approval for calcipotriene cream, 0.005% - the generic version of Dovonex cream, which registered an annual sales of $92.8 mn in the US
BS B2B Bureau B2B Connect | Mumbai
)
Glenmark will market this product upon receiving final approval of its calcipotriene cream, 0.005% ANDA. The patents listed in the Orange Book for Dovonex cream are scheduled to expire on June 9, 2015.
Dovonex is indicated for the treatment of plaque psoriasis. According to IMS Health sales data for the 12 month period ending March 2015, the Dovonex market achieved annual sales of approximately $ 92.8 million.
More From This Section
Don't miss the most important news and views of the day. Get them on our Telegram channel
First Published: May 04 2015 | 6:16 PM IST